Request Demo
Fierce Pharma Asia—Merck KGaA and Hengrui's PARP deal; Novartis and Takeda's employee dispute; toripalimab's FDA nod
Drug ApprovalADCLicense out/inAcquisition
Merck KGaA and Hengrui's PARP1 licensing deal, Novartis' request for discovery against Takeda and the FDA's first approval for a China-made PD-1 inhibitor made our news this week.
Merck KGaAays $169M for selecPARP1 inhibitorPARP1PARP1 drug, stepHengrui cNovartis to AstraZeneca and GileadFDAJunshiPD-1toripalimab
MerMerckaA is paying 160 million ePARP1for ex-China rights to Jiangsu HAstraZenecamaceuGilead’ PARP1 inhibitor, HRS-1167, with 1.6 billion euros lined up as potential milestones. Merck’s betting that a PARP1-specific inhibitor might avoid some hematologic toxicity that has limited the dosing and combinability of existing PARP1/2 inhibitors such as Merck & Co. and AstraZeneca’s Lynparza.
Merck KGaAs claims ex-staffer jumped to Takeda with 'thousandsJiangsu Hengrui PharmaceuticalsPARP1 inhibitorPARP1HRS-1167MerckPARP1-specific inhibitorPARP1-specificPARP1/2 inhibitorsMerck & Co.AstraZenecaLynparza
NovNovartislieves a former employee jumped ship to Takeda this year after transferring around 10,000 files to his personal email. The staffer, Khaled Shams Eldin, was previously operations lead for cell and gene therapy at Novartis’ Egypt branch. He joined Takeda Egypt as divestment and contract manufacturing implementation lead. Novartis is seeking a subpoena to look at certain Takeda documents.
Novartisus rejects 'heavily discounted' pricing on Loqtorzi, the first China-made PD-1 drug to win FDA nodNovartisTakeda EgyptNovartis
AftCoherusgulatory saga, Coherus BioSciences has woLoqtorzirst FDA approval for a PD-1 druge PD-1 iFDAbitor. The company’s Junshi Biosciences-partnered toripalimab became the first FDA-approved therapy for metastatic nasopharyngeal carcinoma. Although PD-1 inhibitors are notably cheap in China, Coherus won’t adopt “heavily discounted pricing” for its drug in the U.S., CEO Denny Lanfear said.
4. Daiichi Sankyo ups revCoherus BioSciencess to massive Merck FDAlPD-1Junshi BiosciencestoripalimabFDAmetastatic nasopharyngeal carcinomaPD-1Coherus
DaiDaiichi Sankyo absorb manufacturing units in move to lMerckge ADC strength
Daiichi Sankyo has increased its revenue forecast for the current fiscal year by 100 billion Japanese yen ($660 million) to a total of 1.55 billion yen. The company cited the newly signed antibody-drug conjugate deal with Merck & Co., Enhertu’s revenue and foreign exchange for the adjustment. The Japanese pharma also plans an internal merger to absorb two manufacturing subsidiaries.
Daiichi Sankyolympus laparoscopic insufflation hardware recall to 10 injuries, one deathMerck & Co.
TheFDAA recenOlympuseled Olympus’ corrective actions for a problem with its UHI-4 insufflation hardware a Class I recall, the agency’s most serious. The agency said it received reports of 21 malfunctions, including 10 serious injuries and one death. The reports described incidents where elevated air pressure the Olympus equipment induced within the abdomen interfered with heartbeats.
6. Aragen to beef up biologics manufacturing, investing $30M in new site in India
7. Aragenan, the CRO formerly known as Alliance, makes move into China with Denali acquisition
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.